LYCA Stock Forecast: Lycia Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Lycia Therapeutics, Inc. hold a median 12-month price target of $49 — +48.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lycia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (30): Analysts have, on balance, been raising their forecasts.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LYCA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LYCA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +48.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | Evercore ISI Group | Initiates | Outperform | $43 |
| 17 Nov 2026 | Jefferies | Initiates | Buy | $50 |
| 17 Nov 2026 | LifeSci Capital | Initiates | Outperform | $48 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LYCA.
This page is one stock. Monday covers all of them.
LYCA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LYCA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LYCA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 388.4×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- —
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lycia Therapeutics, Inc. has a market value of $1.7B and an enterprise value of $640.4M.
Lycia Therapeutics, Inc. employs 31 people.
Data provided by Twelve Data
LYCA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LYCA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lycia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LYCA
What is the LYCA stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Lycia Therapeutics, Inc. have a median 12-month price target of $49, with estimates ranging from $43 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LYCA stock a buy right now?
Of the 5 analysts covering Lycia Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lycia Therapeutics, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LYCA?
As at 21 Nov 2026, Lycia Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (30 of 100).
Will LYCA stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +48.2% from the last close, and Ticker Nerd's factor model ranks Lycia Therapeutics, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LYCA stock forecast for 2030?
No analyst covering Lycia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LYCA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $75 over the next 12 months.
What does Lycia Therapeutics, Inc. do?
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that remove disease-driving proteins from outside cells. Its core technology, the lysosomal targeting chimera platform, is designed to direct soluble and membrane-bound extracellular proteins to lysosomes, the cell’s natural waste-processing compartments, for degradation.
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that remove disease-driving proteins from outside cells. Its core technology, the lysosomal targeting chimera platform, is designed to direct soluble and membrane-bound extracellular proteins to lysosomes, the cell’s natural waste-processing compartments, for degradation. This approach supports the development of targeted protein degraders for conditions in oncology, immunology, inflammation, and other areas of significant unmet medical need. The company’s current pipeline includes cataLYTAC programs such as LCA-0061, focused on allergic disease, and LCA-0321, directed toward Graves’ disease. By addressing proteins that may be difficult to inhibit with conventional drug modalities, Lycia Therapeutics, Inc. operates at the intersection of protein biology, drug discovery, and precision medicine. Headquartered in South San Francisco, California, the company represents a specialized biotechnology business focused on translating extracellular protein degradation into potential therapeutic products.
CEO Dr. Aetna Wun Trombley Ph.D. · 31 employees · United States · https://lyciatx.com